Skip to content

Effects of Exercise Training on Fluid Instability in Heart Failure Patients

Effects of Exercise Training on Fluid Instability in Heart Failure Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01375673
Enrollment
14
Registered
2011-06-17
Start date
2011-11-30
Completion date
2014-12-31
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Exercise, Heart Failure, Mixed Effects Modeling

Brief summary

Heart Failure (HF) is a significant healthcare concern in the US, with a 120% rise in mortality rates over 15 years costing the country an estimated $37.2 billion in 2009. Veterans are currently impacted at a rate of 5.2%, and cost an average of $14,959/individual/year for those utilizing the VA's Healthcare services. Research has shown that exercise training (ET) improves aerobic capacity, endothelial dysfunction, quality of life, and the ability to tolerate activity within the overall HF population. The purpose of this study is to examine the effects of structured exercise training and specific types of exercise training, walking, bicycling, and resistance training, on the symptom of fluid volume over load or edema in advanced heart failure patients.

Detailed description

Background: Heart Failure (HF) is a significant healthcare concern in the US, with a 120% rise in mortality rates over 15 years costing the country an estimated $37.2 billion in 2009. Veterans are currently impacted at a rate of 5.2%, and cost an average of $14,959/individual/year for those utilizing the VA's Healthcare services. Research has shown that exercise training (ET) improves aerobic capacity, endothelial dysfunction, quality of life, and the ability to tolerate activity within the overall HF population. Animal models have emerged to explain some of the underlying mechanisms for the pathologic expression of symptoms and the links to ET. A translational link has not yet been explored between the animal models and human symptom expression. Objectives: The long-term goal of this research program is to develop an exercise training (ET) program that effectively decreases fluid shift variability in HF patients, while being safely implemented in the home environment and remotely monitored by a healthcare provider within a nurse-lead HF Clinic. The purpose of the proposed research project is to determine if ET alters fluid status of patients with HF as compared to those under standard treatment of care. The central hypothesis is that a combined weight-bearing aerobic and resistance ET protocol will reduce (stabilize) 24-hour weight and bioelectrical impedance patterns of variability, as evaluated via mixed-effects regression modeling, greater than any other form of ET protocol. Methods: Design: Using established experimental design techniques implemented in an innovative manner, a between-group design is used within the experimental arm employing a single subject, multiple-baseline design. The use of such technique allows for the subjects to be their own controls, while also allowing for statistical between group comparisons. Subjects and Setting: 60 subjects meeting inclusion/exclusion criteria will be enrolled from the VA HF Clinic and outpatient VA cardiology clinics within 50 miles of Columbia, South Carolina. Subjects will be randomized to the exercise or usual care groups. Procedures: The exercise protocol lasts 12 weeks, with subjects being randomized to order of ET. Weight-bearing aerobic ET will be walking on a treadmill; non-weight-bearing aerobic ET will be stationary bicycling; and resistance ET will be lower body isolation ET. Fluid stability is the concept of day-to-day variability of movement of intra-cellular fluid to extra-cellular space. Fluid stability will be assessed using 24-hour weight and bioelectrical impedance and quantified statistically using mixed effect modeling. Data Analysis: Statistical analysis will utilize a longitudinal mixed-effects regression model, modeling variability over time for the subjects individually, as well as within groups. Additionally, main effects (time and group) and interaction effects (time by group) will be assessed. Status: Funding began September 1, 2010. The study was transferred to Dorn VAMC in Columbia, SC in March of 2011. Currently the study is in the final phase of data analysis.

Interventions

OTHERExercise

Walking Strength Training Bicycling

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Advanced Heart Failure * Ability to Walk * Over 21

Exclusion criteria

* Renal Failure * Inability to walk * Physician exclusion

Design outcomes

Primary

MeasureTime frameDescription
Bioelectrical Impedance Changebaseline, week 16, week 24The extracellular fluid was calculated and reported to demonstrate Fluid Instability. A Bioelectrical Impedance Monitor was utilized to attain these measures.

Secondary

MeasureTime frameDescription
Body Weight Changebaseline, week 16, week 24Body weight was assessed via a home weight scale. Patients recorded their morning body weight in pounds up to 1 decimal point. The daily values were then used to create a weekly standard deviation to represent variability of daily weight. The standard deviation was then meaned for phase of the study. The values reported represent absolute weight means across participants.
Health Outcome Measures Changebaseline, week 16, week 24Health Outcomes were measured with a Daily Heart Failure Symptom Questionnaire. The likert scale was converted to a continuous scale ranging from 0-15 for each of the 10 questions. The higher scores are more indicative of active HF symptoms while lower scores are lack of active HF symptoms. Range for this total score is 0-150.

Countries

United States

Participant flow

Recruitment details

98 subjects were screened. Of the 98, 15 were female, 21 meet both inclusion and exclusion criteria, and 16 began the enrollment process. Of those 16 subjects, 1 died prior to full consent, 1 choose not to enroll.

Participants by arm

ArmCount
Exercise
Exercise: Walking Strength Training Bicycling
7
Standard of Care
Standard of Care
7
Total14

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicExerciseStandard of CareTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
7 Participants7 Participants14 Participants
Ejection Fraction
25% and less EF
3 Participants3 Participants6 Participants
Ejection Fraction
26-40% EF
2 Participants3 Participants5 Participants
Ejection Fraction
41% and greater EF
2 Participants1 Participants3 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants0 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants7 Participants13 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
4 Participants3 Participants7 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
3 Participants4 Participants7 Participants
Region of Enrollment
United States
7 Participants7 Participants14 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
7 Participants7 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 7
other
Total, other adverse events
0 / 70 / 7
serious
Total, serious adverse events
0 / 70 / 7

Outcome results

Primary

Bioelectrical Impedance Change

The extracellular fluid was calculated and reported to demonstrate Fluid Instability. A Bioelectrical Impedance Monitor was utilized to attain these measures.

Time frame: baseline, week 16, week 24

Population: BioImpedence/Extracellular vs intracellular fluid analyzed daily for 24 weeks. Daily values compressed into mean for week x 24 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
ExerciseBioelectrical Impedance ChangeBaseline-Week 447.52 Percentage of Extra Cellular FluidStandard Deviation 1.5
ExerciseBioelectrical Impedance ChangeIntervention-Week 1641.27 Percentage of Extra Cellular FluidStandard Deviation 2
ExerciseBioelectrical Impedance ChangeMaintenance-Week 2442.1 Percentage of Extra Cellular FluidStandard Deviation 1.7
Standard of CareBioelectrical Impedance ChangeBaseline-Week 447.1 Percentage of Extra Cellular FluidStandard Deviation 1.35
Standard of CareBioelectrical Impedance ChangeIntervention-Week 1646.8 Percentage of Extra Cellular FluidStandard Deviation 1.45
Standard of CareBioelectrical Impedance ChangeMaintenance-Week 2447.0 Percentage of Extra Cellular FluidStandard Deviation 1.4
Secondary

Body Weight Change

Body weight was assessed via a home weight scale. Patients recorded their morning body weight in pounds up to 1 decimal point. The daily values were then used to create a weekly standard deviation to represent variability of daily weight. The standard deviation was then meaned for phase of the study. The values reported represent absolute weight means across participants.

Time frame: baseline, week 16, week 24

Population: Daily weight was recorded in pounds and then converted into a weekly standard deviation

ArmMeasureGroupValue (MEAN)Dispersion
ExerciseBody Weight ChangeIntervention-Weeks 5-16242 PoundsStandard Deviation 0.45
ExerciseBody Weight ChangeMaintenance-Weeks 17-24258 PoundsStandard Deviation 0.95
ExerciseBody Weight ChangeBaselline-Weeks 1-4249 PoundsStandard Deviation 2.14
Standard of CareBody Weight ChangeIntervention-Weeks 5-16260 PoundsStandard Deviation 1.9
Standard of CareBody Weight ChangeMaintenance-Weeks 17-24261 PoundsStandard Deviation 1.85
Standard of CareBody Weight ChangeBaselline-Weeks 1-4256 PoundsStandard Deviation 1.88
Secondary

Health Outcome Measures Change

Health Outcomes were measured with a Daily Heart Failure Symptom Questionnaire. The likert scale was converted to a continuous scale ranging from 0-15 for each of the 10 questions. The higher scores are more indicative of active HF symptoms while lower scores are lack of active HF symptoms. Range for this total score is 0-150.

Time frame: baseline, week 16, week 24

Population: The Heart Failure Questionnaire was assessed as a daily measure with weekly mean and SD being reported for each phase. The Likert Scale was converted to a continuous scale from 0 to 15 cm and scores added together for the 10 questions to get a total score.

ArmMeasureGroupValue (MEAN)Dispersion
ExerciseHealth Outcome Measures ChangeMaintenance-Week 2428.55 Total PointsStandard Deviation 3
ExerciseHealth Outcome Measures ChangeBaseline-Week 425.05 Total PointsStandard Deviation 1.48
ExerciseHealth Outcome Measures ChangeIntervention-Week 1618.2 Total PointsStandard Deviation 1.7
Standard of CareHealth Outcome Measures ChangeMaintenance-Week 2429.5 Total PointsStandard Deviation 1.8
Standard of CareHealth Outcome Measures ChangeBaseline-Week 427.25 Total PointsStandard Deviation 1.52
Standard of CareHealth Outcome Measures ChangeIntervention-Week 1628.25 Total PointsStandard Deviation 1.75

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026